Francis Plat, MD
Chief Scientific Officer
Dr. Plat has served as Milestone’s Chief Scientific Officer since February 2022, prior to which he was the company’s Chief Medical Officer since June 2015. Dr. Plat brings over 24 years of international experience in clinical research, having worked within a number of global pharmaceutical companies. Prior to joining Milestone, he was vice president and therapeutic area head, Atherosclerosis and Cardiovascular, at Merck Research Laboratories. Dr. Plat has been involved in the development and repositioning of numerous cardiovascular compounds (Vytorin, anacetrapib, vorapaxar, betrixaban, Brinavess, Effient, Azor, edoxaban, Diovan, Tareg (valsartan), Aprovel, Avalide (irbesartan), gemopatrilat, sotalol, Captopril), from ‘proof of concept’ through to registration and approval. Dr. Plat also held positions at Novartis, where he was responsible for global clinical trials as Vice President of Cardiovascular Clinical Research, and Daiichi Sankyo as Vice President of Cardiovascular Clinical Development. Dr. Plat began his career at Bristol Myers-Squibb in 1989 where he occupied several positions of responsibility including Medical Director in France and International Group Leader in Cardiovascular Development.
Dr. Plat received his MD from the University of Paris and is a board-certified cardiologist. He spent 10 years practicing medicine in France, including post-cardiovascular surgery at the intensive care unit in the Hospital Marie Lannelongue and in cardiac rehabilitation at Broussais Hospital.